Morphometric Characteristics and Features of Metachronous Breast Cancer

  • Iryna Dyakiv Ivano-Frankivsk National Medical University
  • Anna Kryzhanivska Ivano-Frankivsk National Medical University
Keywords: cancer, morphometric characteristics


An important morphological criterion for the development of the degree of malignancy of breast cancer is the change in the structure of cell nuclei. At the same time, both the morphometric parameters of metachronous breast cancer and their connection with the molecular biological characteristics of these tumors are currently unknown.

         The objective of the research was to identify metachronous malignant disease in the patients with breast cancer.

         Materials and methods. The study is based on a retrospective analysis of tumors in 63 patients with breast cancer, who developed uterine cancer or ovarian cancer within 5 years after diagnosis of breast cancer. All the patients received treatment at the Ivano-Frankivsk Regional Clinical Oncology Center. The criterion for selecting patients in the study was the presence of gynecologic cancer after the treatment of breast cancer. The age of patients with breast cancer involved in the study ranged from 24 to 83 years, averaging 56.8±1.5 years.

            Results and discussion. The maximum values ​​of the perimeter, radius, and area of ​​cell nuclei (19.21±0.7, 3.05±0.4 and 36.3±0.9, respectively) were observed in tumors of the patients with metachronous breast cancer.
The improvement of the perimeter, radius, and area of ​​tumor cell nuclei in the patients with metachronous breast cancer was associated with an increase in the size of the tumors and the presence of metastases in regional lymph nodes.

         Conclusions. The morphometric sign of the high risk of developing metachronous breast cancer is the increase in the perimeter, radius, and cell nucleus area on the background of increased proliferative activity of low-grade cancer in the presence of large tumors and metastases in regional lymph nodes.


Adamov AA. Natsionalnyy proekt "Zdorovye": novyy kurs, novaya strategiya. 2008;1-4.

Bit-Sava EM, Belogurova MB. Hereditary breast cancer. Sibirskiy onkologicheskiy zhurnal. 2012;42-45. [published in Russian]

Shchepotin IB, Fedorenko ZP. Biuleten Natsionalnoho kantser-reiestru Ukraiiny 2015-2016. 2016;17.

Kovalev AA, Tsvetaeva-Berest TV, Grudinskaya TV et al. Expression of protein Pgp, MRP1, and BCRP and effectiveness of chemotherapy in patients with breast cancer. Oncology. 2016;16:269-274.

Boyle DP, McCourt CM, Matchett KB et al. Molecular and clinicopathological markers of prognosis in breast cancer. Expert Rev Mol Diagn. 2013;13(5):481-98. DOI: [PMid:23782255]

Cardoso F, Costa A, Senkus E et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017;1;28(1):16-33. DOI: [PMid:28177437 PMCid:PMC5378224]

Colleoni M, Viale G, Zahrieh D et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol. 2008;19:465-472. DOI: [PMid:17986623]

Conzen SD, Conzen TA, Grushko OI. The Molecular Biology of Breast Cancer. Principles & Practice of Oncology. 2008;8:1595-1654.

Fehm T, Maul H, Gebauer S et al. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor. Strahlenther Onkol. 2005;181(9):580-586. DOI: [PMid:16170485]

Fitzgibbons PL, Page DL, Weaver D et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):966-978.

Original Research